Research Library › Neuropeptides
DSIP, or delta sleep-inducing peptide (INN emideltide), is a nine-amino-acid peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) isolated from rabbit blood by Marcel Monnier and Guido Schoenenberger at the University of Basel, who published its sequence in 1977. No receptor, gene or parent protein for it has ever been identified. DSIP is not FDA-approved, and in July 2026 an FDA advisory committee voted 6–7 against adding it to the pharmacy compounding list.
Key facts
| Type | Nine-amino-acid peptide (nonapeptide) |
|---|---|
| Other names | Delta sleep-inducing peptide; emideltide (INN) |
| Sequence | Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu |
| First described | 1977, sequence published in PNAS |
| Developed by | Marcel Monnier and Guido Schoenenberger, University of Basel, Switzerland |
| Designed target | Unknown; no receptor, gene or precursor protein identified |
| Regulatory status (Oct 2026) | Not FDA-approved; FDA PCAC voted 6–7 against compounding eligibility in July 2026; no final FDA decision |
Who developed it
DSIP was discovered by physiologist Marcel Monnier and biochemist Guido Schoenenberger at the University of Basel in Switzerland. Their group published the peptide’s characterization and sequence in 1977 [1][2], and Schoenenberger later reviewed its chemistry in detail [3].
What it was designed to target
DSIP was not designed; it was isolated. In experiments that began in the 1960s, the Basel team electrically stimulated the thalamus of rabbits and collected blood draining from their brains. They filtered this blood (a process called dialysis) and transferred the filtrate into recipient rabbits, then recorded the recipients’ electroencephalograms for increases in slow, delta-frequency brain waves [4][2]. Over the following decade they purified the active component and identified it as a nine-residue peptide [1][2].
Despite nearly five decades of research, no specific receptor for DSIP has been found, and no gene or larger precursor protein that encodes it has been confirmed [1][5]. A 2006 review in the Journal of Neurochemistry described the peptide as a still-unresolved riddle [6].
The rabbit peptide is catalogued in the UniProt protein database from its 1977 sequence data, but most naturally occurring neuropeptides are traced to a larger precursor encoded by a known gene, and DSIP remains an exception [5].
Why it was created
The work was meant to test a long-standing hypothesis in sleep physiology: that a chemical sleep factor circulates in the blood and could be isolated and identified [3][4]. DSIP was the Basel group’s candidate for that factor. Small clinical research studies were conducted in the 1980s and early 1990s, including a 1992 double-blind study in a research program on chronic insomnia [7].
Research timeline
- 1966: Monnier’s group reports humoral transmission of sleep-associated EEG patterns between rabbits [4].
- 1977: Peptide characterized and sequence published [1][2].
- 1984: Schoenenberger publishes a major review of DSIP’s properties [3].
- 1984–1992: Small clinical research studies are conducted [7].
- 2006: Review calls DSIP a still-unresolved riddle [6].
- July 2026: FDA advisory committee votes 6–7 against compounding eligibility [8][9].
Regulatory status as of October 2026
As of 22 Oct 2026, DSIP is not FDA-approved for any use.
At its 23–24 July 2026 meeting, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) considered emideltide for the 503A bulks list. The committee voted 6–7 against, making DSIP the only one of the seven peptides reviewed at that meeting that the committee did not recommend [8][9][10]. The vote is advisory, and the FDA had not published a final decision as of 22 Oct 2026.
On 14 Oct 2026 the FDA sent an interim access policy for compounding with certain peptides to the White House for review. Its contents were not public and it was not final as of 22 Oct 2026 [11].
Available from Kalibra Labs
Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.
Frequently asked questions
Who discovered DSIP?
DSIP was discovered by Marcel Monnier and Guido Schoenenberger at the University of Basel, Switzerland, who published its sequence in 1977.
What does DSIP stand for?
DSIP stands for delta sleep-inducing peptide. The name refers to the delta-wave EEG activity measured in the rabbit experiments that led to its isolation. Its international nonproprietary name is emideltide.
Is DSIP FDA approved?
No. As of 22 Oct 2026 DSIP is not FDA-approved, and an FDA advisory committee voted 6–7 against adding it to the compounding list in July 2026.
What receptor does DSIP bind to?
None has been identified. Despite decades of study, no receptor, gene or precursor protein for DSIP has been confirmed.
How was DSIP discovered?
Researchers in Basel stimulated the thalamus of rabbits, dialyzed the blood leaving the brain and transferred it into other rabbits while recording their EEG. The active component was purified and sequenced in 1977.
Sources
- Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. PNAS. 1977;74(3):1282–1286. PMID 265572. Link
- Schoenenberger GA, Maier PF, Tobler HJ et al. A naturally occurring delta-EEG enhancing nonapeptide in rabbits. Pflügers Arch. 1977;369:99–109. doi:10.1007/BF00591565 Link
- Schoenenberger GA. Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP). Eur Neurol. 1984;23(5):321–345. Link
- Schneiderman N, Monnier M, Hösli L. Humoral transmission of sleep. IV. Pflügers Arch. 1966;288:65–80. doi:10.1007/BF00412535 Link
- UniProt/Swiss-Prot entry P01158, Delta sleep-inducing peptide (rabbit). Link
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006. PMID 16539679. Link
- Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: a double-blind study. Neuropsychobiology. 1992;26(4):193–197. Link
- Eglovitch JS. FDA advisory committee backs two more peptides, rejects one for compounding list. Regulatory Focus (RAPS), 24 Jul 2026. Link
- Moeller M. FDA Advisory Committee recommends adding six of seven peptides to compounding list. American Med Spa Association, 24 Jul 2026. Link
- U.S. FDA, CDER. Pharmacy Compounding Advisory Committee, 24 Jul 2026: FDA presentation on emideltide, epitalon and semax. Link
- Office of Information and Regulatory Affairs (reginfo.gov). HHS/FDA, Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94: received 14 Oct 2026, pending review. Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.
